SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Update

Key Points

• Short interest increased 20.3% in March to 254,959 shares (about 0.4% of the stock), with a short-interest ratio of 2.6 days, signaling a modest rise in bearish positioning.
• Mount Sinai will adopt SOPHiA GENETICS' SOPHiA DDM platform, a notable commercial win that could drive recurring volume, boost U.S. credibility, and validate demand for AI-driven genomics.
• SOPHiA missed the March-quarter EPS consensus (reported -$0.28 vs. expected -$0.20) and shows negative margins and ROE; analysts forecast about -0.96 EPS for the year, which may constrain valuation until a path to profitability emerges.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) was the target of a significant increase in short interest in March. As of March 31st, there was short interest totaling 254,959 shares, an increase of 20.3% from the March 15th total of 211,974 shares. Currently, 0.4% of the company's stock are sold short. Based on an average daily volume of 96,355 shares, the short-interest ratio is currently 2.6 days.

SOPHiA GENETICS News Roundup

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Large commercial win — Mount Sinai Health System will adopt SOPHiA GENETICS' AI-powered SOPHiA DDM™ platform to support precision cancer care and genomic testing at an NCI-designated cancer center; this enhances U.S. credibility and could drive recurring platform volume from a major health system. Read More.
• Positive Sentiment: Sector validation — press coverage on Mount Sinai using AI to speed genomic testing reinforces demand for AI-driven genomics platforms like SOPHiA DDM, supporting adoption tailwinds and future revenue potential. Read More.
• Positive Sentiment: Analyst support — select firms (BTIG, Guggenheim) have raised price targets and maintain buy ratings, providing upside reference points versus current levels and helping investor sentiment. Read More.
• Neutral Sentiment: Insider sales disclosed — multiple insiders (CEO Jurgi Camblong, President Ross Muken, and others) sold shares in mid‑April. All trades were executed under pre-arranged Rule 10b5-1 plans and many were described as tax-withholding sales tied to vested awards, which lessens governance concern but increases share supply. Read More.
• Negative Sentiment: Earnings and profitability pressure — SOPH reported a March-quarter EPS miss (reported ($0.28) vs. consensus ($0.20)), with negative net margins and a large negative ROE; analysts still expect FY losses (~-0.96 EPS), which can cap valuation and limit multiple expansion until a clear path to profitability is shown. Read More.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on SOPH shares. Weiss Ratings reissued a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. BTIG Research increased their target price on shares of SOPHiA GENETICS from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Wednesday. Finally, Guggenheim increased their target price on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a "buy" rating in a research note on Monday, January 26th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $7.50.

SOPHiA GENETICS Price Performance

SOPH stock traded up $0.16 during mid-day trading on Friday, reaching $5.28. The company's stock had a trading volume of 94,798 shares, compared to its average volume of 179,935. The stock has a market cap of $361.42 million, a PE ratio of -10.36 and a beta of 1.04. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01. SOPHiA GENETICS has a fifty-two week low of $2.58 and a fifty-two week high of $5.70. The company's 50 day moving average is $4.75 and its two-hundred day moving average is $4.72.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.08). The firm had revenue of $21.71 million for the quarter, compared to analyst estimates of $21.20 million. SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%. Equities research analysts expect that SOPHiA GENETICS will post -0.96 EPS for the current year.

Insider Activity

In related news, CEO Jurgi Camblong sold 43,129 shares of the company's stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $4.96, for a total value of $213,919.84. Following the transaction, the chief executive officer directly owned 3,664,440 shares of the company's stock, valued at $18,175,622.40. This represents a 1.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 181,300 shares of company stock worth $880,323 over the last 90 days. Corporate insiders own 4.88% of the company's stock.

Institutional Investors Weigh In On SOPHiA GENETICS

Institutional investors have recently modified their holdings of the company. Alta Wealth Advisors LLC acquired a new stake in SOPHiA GENETICS during the 3rd quarter worth $6,708,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock worth $25,341,000 after acquiring an additional 5,432,871 shares in the last quarter. Archon Capital Management LLC raised its stake in SOPHiA GENETICS by 3.4% during the 4th quarter. Archon Capital Management LLC now owns 441,413 shares of the company's stock worth $2,061,000 after acquiring an additional 14,342 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in SOPHiA GENETICS by 24.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company's stock worth $148,000 after acquiring an additional 6,205 shares in the last quarter. Finally, Polen Capital Management LLC acquired a new stake in SOPHiA GENETICS during the 4th quarter worth $102,000. 31.59% of the stock is owned by hedge funds and other institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.